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Surfactants are potent stabilizers of proteins, preventing protein unfolding and aggregation presumably by 
competitive adsorption to interfaces. Due to limited data on e.g. performance and safety, only three surfactants 
are routinely found within marketed formulations of parenteral protein products: polysorbate 20 (PS20), 
polysorbate 80 (PS80), or poloxamer 188 (Px188).  
 
These molecules are well-established and safe for parenteral administration but possess liabilities such as 
degradation of the surfactant itself and/or chemical inhomogeneity (PS) or show decreased stabilizing effects at 
silicone oil-water interfaces (Px188). Thus, there is a need to evaluate alternative surfactants to expand the 
toolbox for product development and to ensure optimal drug product stability and quality.  
In our studies, potential alternative surfactants were evaluated and compared to PS20 and Px188 (e.g. during   
real-time and stress stability studies using a model mAb). Data from these efforts will be presented. 
 
